Umbilical Cord Blood-Derived Lymphocyte Therapy

BIOLOGICAL2 trials

Sponsors

M.D. Anderson Cancer Center

Conditions

Hematopoietic and Lymphoid Cell NeoplasmPlasma Cell LeukemiaPlasma Cell Myeloma

Phase 1

Donor Cord Blood T-Cell Infusion After Stem Cell Transplant in Treating Patients With Relapsed Hematological Malignancies

TerminatedNCT01630564

M.D. Anderson Cancer CenterHematopoietic and Lymphoid Cell Neoplasm

Start: 2013-03-11End: 2018-05-30Updated: 2018-11-13

Phase 2

Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma

CompletedNCT01729091

M.D. Anderson Cancer CenterPlasma Cell Leukemia, Plasma Cell Myeloma

Start: 2013-06-10End: 2024-06-25Updated: 2025-05-09

Related Papers

Phase II study of umbilical cord blood–derived natural killer (CB-NK) cells with elotuzumab, lenalidomide, and high-dose melphalan followed by autologous stem cell transplantation (ASCT) for patients with high-risk multiple myeloma (HRMM).

Journal of Clinical Oncology2022-06-014 citations

Phase II study of ex vivo expanded cord blood natural killer cells for multiple myeloma.

Journal of Clinical Oncology2018-05-2011 citations

Phase II trial of umbilical cord blood-derived natural killer cells for multiple myeloma.

Journal of Clinical Oncology2016-05-20